AMENDMENTS TO THE CLAIMS

1. (Original) A compound according to Formula II,



Formula II

wherein,

P is aryl;

if m = 1 then R^1 is attached to P at the meta position of the ring P relative to the attachment point of P to the 5-membered ring, and if m = 2 then R^1 is attached to P at the 2-, and 5-positions of the ring P to the 5-membered ring;

R^1 is selected from the group consisting of hydroxy, halo, nitro, C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{1-6}alkyl, OC_{1-6}alkyl, C_{2-6}alkenyl, OC_{2-6}alkenyl, C_{2-6}alkynyl, OC_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, OC_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl, OC_{0-6}alkylaryl, CHO, $(CO)R^5$, $O(CO)R^5$, $O(CO)OR^5$, $O(CN)OR^5$, C_{1-6}alkylOR^5, OC_{2-6}alkylOR^5, C_{1-6}alkyl$(CO)R^5$, OC_{1-6}alkyl$(CO)R^5$, C_{0-6}alkylCO_2R^5, OC_{1-6}alkylCO_2R^5, C_{0-6}alkylcyano, OC_{2-6}alkylcyano, C_{0-6}alkylNR^5R^6, OC_{2-6}alkylNR^5R^6, C_{1-6}alkyl$(CO)NR^5R^6$, OC_{1-6}alkyl$(CO)NR^5R^6$, C_{0-6}alkyl$NR^5(CO)R^6$, OC_{2-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)NR^5R^6$, C_{0-6}alkylSR^5, OC_{2-6}alkylSR^5, C_{0-6}alkyl$(SO)R^5$, OC_{2-6}alkyl$(SO)R^5$, C_{0-6}alkylSO_2R^5, OC_{2-6}alkylSO_2R^5, C_{0-6}alkyl$(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)NR^5R^6$,C_{0-6}alkyl$NR^5(SO_2)R^6$, OC_{2-6}alkyl$NR^5(SO_2)R^6$, C_{0-6}alkyl$NR^5(SO_2)NR^5R^6$, OC_{2-6}alkyl$NR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6, C_{0-6}alkyl$NR^5(CO)OR^6$, OC_{2-6}

$_{6}$alkylNR^{5}(CO)OR^{6}, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R^5 and R^6 are independently selected from a group consisting of hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl and aryl;

X^1 and X^2 are independently selected from the group consisting of CR^4, and N;

X^3 is selected from the group consisting of CR^4, N, and O; wherein at least one of X^1 X^2 and X^3 is not N;

R^4 is selected from the group consisting of H, =O, C_{1-6}alkyl, OH;

R^3 is selected from the group consisting of H, C_{1-6}alkyl, hydroxy, C_{0-6}alkylcyano, oxo, =NR^{5}, =NOR^{5}, C_{1-4}alkylhalo, halo, C3-7cycloalkyl, O(CO)C_{1-4}alkyl, C_{1-4}alkyl(SO)C_{0-4}alkyl, C_{1-4}alkyl(SO_2)C_{0-4}alkyl, (SO)C_{0-4}alkyl, (SO_2)C_{0-4}alkyl, OC_{1-4}alkyl, C_{1-4}alkylOR^{5} and C_{0-4}alkylNR^{5}R^{6};

X^4 is selected from the group consisting of CR^7R^8, NR^7, O, S, SO, and SO_2;

R^7 and R^8 are independently selected from a group consisting of hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl and aryl;

X^5 and X^6 are independently selected from the group consisting of C, N, O and S;

R^2 is selected from the group consisting of hydroxy, C_{0-6}alkylcyano, =NR^{5}, =NOR^{5}, C_{1-4}alkylhalo, halo, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{0-6}alkylaryl, C_{0-},

$_{6}$alkylheteroaryl, C_{0-6}alkylcycloalkyl, C_{0-6}alkylheterocycloalkyl, OC_{1-4}alkyl, OC_{0-6}alkylaryl, O(CO)C_{1-4}alkyl, (CO)OC_{1-4}alkyl, C_{0-4}alkyl(S)C_{0-4}alkyl, C_{1-4}alkyl(SO)C_{0-4}alkyl, C_{1-}

$_4$alkyl$(SO_2)C_{0-4}$alkyl, $(SO)C_{0-4}$alkyl, $(SO_2)C_{0-4}$alkyl, C_{1-4}alkylOR^5, C_{0-4}alkylNR^5R^6 and a 5- or 6-membered ring containing atoms independently selected from C, N, O and S, and wherein said ring may be substituted by one or more A; and

any C_{1-6}alkyl, aryl or heteroaryl defined under R^1, R^2 and R^3 may be substituted by one or more A;

A is selected from the group consisting of hydrogen, hydroxy, halo, nitro, oxo, C_{0-6}alkylcyano, C_{0-4}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{2-6}alkenyl, C_{0-3}alkylaryl, C_{0-6}alkylOR^5, OC_{2-6}alkylOR^5, C_{1-6}alkylSR^5, OC_{2-6}alkylSR^5, $(CO)R^5$, $O(CO)R^5$, OC_{2-6}alkylcyano, OC_{1-6}alkylCO_2R^5, $O(CO)OR^5$, OC_{1-6}alkyl$(CO)R^5$, C_{1-6}alkyl$(CO)R^5$, NR^5OR^6, C_{1-6}alkylNR^5R^6, OC_{2-6}alkylNR^5R^6, C_{0-6}alkyl$(CO)NR^5R^6$, OC_{1-6}alkyl$(CO)NR^5R^6$, OC_{2-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)NR^5R^6$, $O(CO)NR^5R^6$, C_{0-6}alkyl$(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)NR^5R^6$, C_{0-6}alkyl$NR^5(SO_2)R^6$, OC_{2-6}alkyl$NR^5(SO_2)R^6$, SO_3R^5, C_{1-6}alkyl$NR^5(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)R^5$, C_{0-6}alkyl$(SO_2)R^5$, C_{0-6}alkyl$(SO)R^5$, OC_{2-6}alkyl$(SO)R^5$ and a 5- or 6-membered ring containing one or more atoms independently selected from the group consisting of C, N, O and S;

m is selected from 1 and 2;

n is selected from 0, 1, 2, 3 and 4;

p is selected from 1 and 2; and

and a salts or hydrates thereof,

2. (Original) A compound according to claim 1 wherein P is phenyl.

3. (Original) A compound according to claim 1 wherein X^4 is selected from CR^7R^8, NR^7, O and S.

4. (Original) A compound according to claim 1 wherein X^5 is N.

5 (Original) A compound according to claim 4 wherein X^6 is N.

6. (Original) A compound according to claim 4 wherein X^6 is O.

7. (Original) A compounds according to claim 1 wherein X^5 is C and X^6 is N.

8. (Original) A compound according to claim 1 wherein R^2 is selected from aryl and C_{0-6}heteroaryl

9. (Original) A compound according to claim 1 wherein R^2 is selected from 4-pyridyl, 3-pyridyl and phenyl.

10. (Original) A compound according to claim 1 wherein R^2 is a 5- or 6-membered ring containing atoms independently selected from C, N, O and S, which ring may be substituted by one or more A.

11. (Original) A compound according to claim 1 wherein the ring containing X^1, X^2, and X^3 is selected from the group consisting of:

a)  , b)  , c)  , d)  ,

e)  , and f) 

12. (Original) A compound according to claim 1 wherein X^1 and X^2 are N and X^3 is C.

13. (Original) A compound according to claim 1 selected from the group consisting of:

3-(3-chlorophenyl)-5-{[(4-methyl-5-pyridin-3-yl-4H-1,2,4-triazol-3-yl)thio]methyl}-1,3,4-oxadiazol-2(3H)-one

2-(3-chlorophenyl)-5-{1-[methyl(4-methyl-5-pyridin-4-yl-4H-1,2,4-triazol-3-yl)amino]ethyl}-2,4-dihydro-3H-1,2,4-triazol-3-one

4-(5-{1-[1-(3-chlorophenyl)-1H-pyrazol-4-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

4-(5-{1-[2-(3-chlorophenyl)-2H-1,2,3-triazol-4-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

4-[5-({1-[2-(3-chlorophenyl)-2H-1,2,3-triazol-4-yl]ethyl}thio)-4-cyclopropyl-4H-1,2,4-triazol-3-yl]pyridine

4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,4]triazol-3-ylmethylsulfanyl]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine

4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,4]triazol-3-ylmethoxy]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine

4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,3]triazol-4-ylmethylsulfanyl]-4-methyl-4H-[1,2,4]triazol-3-yl}-pyridine

4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,3]triazol-4-ylmethylsulfanyl]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine

4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,3]triazol-4-ylmethoxy]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine, and

4-(5-{(1*R*)-[2-(3-chlorophenyl)-2*H*-1,2,3-triazol-4-yl]ethoxy}-4-methyl-4*H*-1,2,4-triazol-3-yl)pyridine

14. (Original) A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 to 13, in association with one or more pharmaceutically acceptable diluent, excipients and/or inert carrier.

15. (CANCELLED)

16. (Currently Amended) The compound according to ~~any one of claims 1 to 13~~ claim 1, for use in therapy.

17. (Currently Amended) The compound according to ~~any one of claims 1 to 13~~ claim 1, for use in treatment of mGluR 5 mediated disorders.

18. (Currently Amended) Use of the compound according to ~~any one of claims 1 to 13~~ claim 1, in the manufacture of a medicament for the treatment of mGluR 5 mediated disorders.

19. (Currently Amended) A method of treatment of mGluR 5 mediated disorders, comprising administrering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound according to ~~any one of claims 1 to 13~~ claim 1.

20. (Original) The method according to claim 19, for use in treatment of neurological disorders.

21. (Original) The method according to claim 19, for use in treatment of psychiatric disorders.

22. (Original) The method according to claim 19, for use in treatment of chronic and acute pain disorders.

23. (Original) The method according to claim 19, for use in treatment of gastrointestinal disorders.

24. (Original) A method for inhibiting activation of mGluR 5 receptors, comprising treating a cell containing said receptor with an effective amount of the compound according to claim 1.